CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

– FDA has granted Priority Review with a target PDUFA date of August 14 – NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks